Previous close | 56.05 |
Open | 45.70 |
Bid | 44.50 |
Ask | 48.70 |
Strike | 300.00 |
Expiry date | 2025-01-17 |
Day's range | 45.60 - 56.05 |
Contract range | N/A |
Volume | |
Open interest | N/A |
On May 16, 2024, Rainer Blair, President & CEO of Danaher Corp (NYSE:DHR), executed a sale of 9,005 shares of the company.
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.